Author: Teva Pharmaceutical Industries Ltd

Posted Date:

May 4, 2026

Teva to Present at the BofA Securities Health Care Conference

Teva Pharmaceutical Industries Ltd

May 4, 2026
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Teva Pharmaceutical Industries Ltd

April 30, 2026
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva Pharmaceutical Industries Ltd

April 29, 2026
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Teva Pharmaceutical Industries Ltd

April 29, 2026
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Teva Pharmaceutical Industries Ltd

April 15, 2026
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Teva Pharmaceutical Industries Ltd

April 14, 2026
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva Pharmaceutical Industries Ltd

March 30, 2026
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Teva Pharmaceutical Industries Ltd

March 19, 2026
Teva Releases Q1 2026 Aide Memoire

Teva Pharmaceutical Industries Ltd

March 19, 2026
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

Teva Pharmaceutical Industries Ltd

March 4, 2026